Interestingly, western analysis did not reveal a pattern specifically implicating either Bcl-2 or Bcl-xL inhibition as a main driver of Mcl-1 upregulation across all three ER+ breast cancer cell lines tested (Figure 1E). The gene discussed is BCL2L1; the disease is breast carcinoma.